Fig. 1 · Structure

Documents & Downloads

Tiotropium Bromide

Cat. No. A10934 CAS 136310-93-5

muscarinic acetylcholine receptor (mAChR) antagonist

Tiotropium Bromide (BA679 BR) is a muscarinic acetylcholine receptor (mAChR) antagonist that blocks the binding of the acetylcholine ligand and subsequent opening of the ligand-gated ion channel.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Tiotropium Bromide Research Summary

This section summarizes 3 in vitro studies of Tiotropium Bromide from 2 published references. In vitro models include BEAS-2B cells.

Tiotropium Bromide In Vitro Studies

In BEAS-2B cells, Tiotropium Bromide at 12.5 pg/mL significantly suppressed LPS-induced IL-8 production compared with its absence, whereas concentrations <10.0 pg/mL did not inhibit this response. In UNCN3T cells, Tiotropium Bromide at 5-50 μM produced no significant difference in mucin secretion compared with culture medium alone. At the same tested concentrations, no significant increase in IL-6 was observed in UNCN3T cells. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

LPS-Induced IL-8 Production in BEAS-2B Cells

Cell-based study · BEAS-2B cells [1]

BEAS-2B cells were treated with Tiotropium Bromide before LPS stimulation. Tiotropium Bromide at <10.0 pg/mL did not inhibit LPS-induced IL-8 production, whereas 12.5 pg/mL significantly suppressed it compared with the absence of Tiotropium Bromide.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
IL-8 levels in culture supernatants were assayed by ELISAReported result Although the addition of tiotropium bromide at concentration <10.0 pg/mL could not inhibit the ability of cells to produce IL-8 in response to LPS stimulation, tiotropium bromide at 12.5 pg/mL significantly suppressed LPS-induced IL-8 production from BEAS-2B cells[1]

Literature-Reported Treatment Conditions

Treatment concentration
<10.0 pg/mL; 12.5 pg/mL; >15.0 pg/mL
Exposure duration
2 hours before the stimulation with LPS; for 24 hours
Method
added to cell cultures
Vehicle
MEDIUM
Co-treatment
Other interventions in this design: LPS 1.0 μg/mL. Compound effect isolated by the comparison: in the presence or absence of tiotropium bromide.
Methods and source locations

Compound reported in the paper: Tiotropium Bromide

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Chemicals (S4); Materials and methods > Cell culture (S26); Results > Suppressive activity of tiotropium bromide on IL-8 production from cells after LPS stimulation (S42, S43, S44)

IL-8 levels in culture supernatants were assayed by ELISA: IL-8 levels in culture supernatants were assayed by ELISA; comparator: absence of tiotropium bromide — Results > Suppressive activity of tiotropium bromide on IL-8 production from cells after LPS stimulation (S42, S43)

Mucin secretion in UNCN3T cells

Cell-based study · UNCN3T cells cultured on Geltrex™-coated plastic; n = 12 (n = 4 in triplicate; three experiments performed on different days) [2]

UNCN3T cells cultured on Geltrex™-coated plastic were incubated with Tiotropium Bromide at 5-50 μM for 30 min. Mucin secretion did not differ significantly from the response to culture medium alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
mucin secretionReported result 5-50 μM: none of the values were significantly different to the response to culture medium alone (P > 0.05).[2]

Literature-Reported Treatment Conditions

Treatment concentration
5-50 μM
Exposure duration
30 min
Method
incubated for 30 min at 37 °C 5% CO2/95% air in control or drug solutions
Vehicle
LHC basal medium
Methods and source locations

Compound reported in the paper: Tiotropium Bromide

Evidence for Tiotropium Bromide as the hydrate form reported in the paper, not the free base/neutral form supplied as A10934; no salt equivalence, dose conversion or lot validation.

Materials and methods > Quantification of cytokine release and mucus secretion in response to treatment with inhaled drugs (S101, S102); Results > The effects of some inhaled drugs on mucus secretion from SPOC1 and UNCN3T cells (S205); Fig. 9 legend (S231, S233)

mucin secretion: mucin secretion; comparator: culture medium alone — Materials and methods > Quantification of cytokine release and mucus secretion in response to treatment with inhaled drugs (S102); Results > The effects of some inhaled drugs on mucus secretion from SPOC1 and UNCN3T cells (S205); Fig. 9 legend (S231)

IL-6 responses in UNCN3T cells

Cell-based study · UNCN3T cells cultured on Geltrex™-coated plastic; n = 12 (4 replicates; three independent experiments) [2]

UNCN3T cells cultured on Geltrex™-coated plastic were incubated with Tiotropium Bromide at 5-50 μM for 30 min. No significant increase in IL-6 was observed compared with cells exposed to culture medium alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
IL-6Reported result 5-50 μM: No significant increase in IL6 was observed for any of the applied drugs (P > 0.05).[2]

Literature-Reported Treatment Conditions

Treatment concentration
5-50 μM
Exposure duration
30 min
Method
incubated for 30 min at 37 °C 5% CO2/95% air in control or drug solutions
Vehicle
LHC basal medium
Methods and source locations

Compound reported in the paper: Tiotropium Bromide

Evidence for Tiotropium Bromide as the hydrate form reported in the paper, not the free base/neutral form supplied as A10934; no salt equivalence, dose conversion or lot validation.

Materials and methods > Quantification of cytokine release and mucus secretion in response to treatment with inhaled drugs (S101, S102); Results > The effects of some inhaled drugs on cytokine release from SPOC1 and UNCN3T cells (S180, S192, S193); Fig. 8 legend (S228, S230)

IL-6: IL-6; comparator: cells exposed to culture medium alone — Materials and methods > Quantification of cytokine release and mucus secretion in response to treatment with inhaled drugs (S102); Results > The effects of some inhaled drugs on cytokine release from SPOC1 and UNCN3T cells (S180, S193)

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 136310-93-5
Applications muscarinic acetylcholine receptor (mAChR) antagonist
Formula C19H22BrNO4S2
Molecular Weight 472.42
Synonyms BA679 BR; BA 679
SMILES
O=C(C(C1=CC=CS1)(O)C2=CC=CS2)O[C@H]3C[C@H]([N+]4(C)C)[C@@H]5O[C@@H]5[C@H]4C3.[Br-]

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 8 mg/mL (16.31 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Tiotropium Bromide Research References

  1. [1] Suzaki I, Asano K, Shikama Y, et al. Suppression of IL-8 production from airway cells by tiotropium bromide in vitro. Int J Chron Obstruct Pulmon Dis (2011). PMID: 22003289 DOI: 10.2147/COPD.S23695 Source material
  2. [2] Lee DF, Lethem MI, Lansley AB. A comparison of three mucus-secreting airway cell lines (Calu-3, SPOC1 and UNCN3T) for use as biopharmaceutical models of the nose and lung. Eur J Pharm Biopharm (2021). PMID: 34332033 DOI: 10.1016/j.ejpb.2021.07.016 Source material

Added to your cart

View Cart Checkout
Loading...